To the full analysis
WuXi Biologics (Cayman) stock: growth
2269.HKWuXi Biologics (Cayman) reported $3.27B in revenue for fiscal 2025, up 16.7% on the prior year, up 31.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
46.3%
per year from 2014 to 2025, per share 43.6%
Earnings (Annual rate)
54.2%
per year from 2014 to 2025, per share 51.2%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2014 | |
|---|---|---|---|
| Revenue | 31.2% | 44.3% | 46.3% |
| Revenue per share | 31.4% | 41.4% | 43.6% |
| Earnings | 23.8% | 60.0% | 54.2% |
| Earnings per share | 22.0% | 56.6% | 51.2% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $49.77M | $6.3M | −$4.43M |
| 2015 | $83.54M | $6.67M | −$34.07M |
| 2016 | $148.32M | $21.16M | −$52.03M |
| 2017 | $242.77M | $37.89M | −$49.11M |
| 2018 | $380.08M | $94.57M | −$160.29M |
| 2019 | $597.41M | $152.03M | −$303.91M |
| 2020 | $841.66M | $253.27M | −$621.38M |
| 2021 | $1.54B | $508.15M | −$463.67M |
| 2022 | $2.29B | $662.88M | −$49M |
| 2023 | $2.55B | $509.84M | $65.56M |
| 2024 | $2.8B | $503.29M | $193.1M |
| 2025 | $3.27B | $736.08M | $419.71M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.